Expanded Access to Ensartinib for Participants With ALK+ NSCLC

Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK

NCT02959619 ·Status: COMPLETED ·Phase: PHASE1

A Real World Study of Ensartinib in Advanced ALK-positive NSCLC

NCT05498064 ·Status: RECRUITING

Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD

NCT06780839 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement

NCT03608007 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer

NCT05380024 ·Status: UNKNOWN ·Phase: PHASE2

Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer

NCT06762327 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

The Efficacy and Safety of Ensartinib As Adjuvant Therapy in Stage I ALK-positive NSCLC Patients with High Risk Factors

NCT06772610 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

NCT03178071 ·Status: NO_LONGER_AVAILABLE

X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases

NCT04415320 ·Status: UNKNOWN ·Phase: PHASE2

An Expanded Access Study of Brigatinib for Patients With ALK-positive Advanced Non-Small Cell Lung Cancer

NCT02784158 ·Status: NO_LONGER_AVAILABLE

Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer

NCT05341583 ·Status: RECRUITING ·Phase: PHASE3

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

NCT03804541 ·Status: UNKNOWN ·Phase: PHASE1

Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer

NCT06779539 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Expanded Access Program of Taletrectinib in Patients With Advanced or Metastatic ROS1-Positive NSCLC

NCT06841874 ·Status: NO_LONGER_AVAILABLE

Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance

NCT05178511 ·Status: UNKNOWN ·Phase: PHASE2

Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

NCT03410108 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma ：A Multicenter, Real-World Clinical Study

NCT06785584 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer

NCT05241028 ·Status: RECRUITING ·Phase: PHASE2

Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer

NCT01998126 ·Status: COMPLETED ·Phase: PHASE1

Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC

NCT07235306 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy

NCT02271139 ·Status: NO_LONGER_AVAILABLE

Real-world Observational Study of Targeted Therapy in Patients With Advanced ROS1-positive NSCLC

NCT06694129 ·Status: NOT_YET_RECRUITING

A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

NCT03535740 ·Status: COMPLETED ·Phase: PHASE2

Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations

NCT05845671 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

NCT01610336 ·Status: COMPLETED ·Phase: PHASE2